Last reviewed · How we verify

NCT04822051

The Effect of Psychoeducation Based on Uncertainty In Illness Theory On Schizophrenia Caregivers

Completed NA Last updated 1 April 2021
What this trial tests

NA trial testing The Uncertainty Management Psychoeducation Program in Psychiatric Nursing in 54 participants. Completed in 31 August 2020.

Timeline
1 April 2019
Primary endpoint
31 August 2020
31 August 2020

Quick facts

Lead sponsorAkdeniz University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment54
Start date1 April 2019
Primary completion31 August 2020
Estimated completion31 August 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Akdeniz University

Who can join

18 and older, any sex, with Psychiatric Nursing or Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the effect of the psychoeducation program based on the Uncertainty in Illness Theory on intolerance to uncertainty, psychological well-being and coping styles of caregivers of schizophrenia patients. Sample was 54 (experimental group:27; control group: 27) caregivers. Experimental group received psychoeducation program (5 sessions) based on Mishel's Reconceptualized Uncertainty in Illness Theory while control group did not receive any intervention. Data were collected 2 times: pre test, post test.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Akdeniz University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04822051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing